Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38019254)

  • 1. Characteristic Mutational Damages in Gastric and Colorectal Adenocarcinomas.
    Yermekova S; Orazgaliyeva M; Goncharova T; Rakhimbekova F; Kaidarova D; Shatkovskaya O
    Asian Pac J Cancer Prev; 2023 Nov; 24(11):3939-3947. PubMed ID: 38019254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational Damages in Malignant Lung Tumors.
    Yermekova S; Orazgaliyeva M; Goncharova T; Rakhimbekova F; Dushimova Z; Vasilieva T
    Asian Pac J Cancer Prev; 2023 Feb; 24(2):709-716. PubMed ID: 36853323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location.
    Gervaz P; Bouzourene H; Cerottini JP; Chaubert P; Benhattar J; Secic M; Wexner S; Givel JC; Belin B
    Dis Colon Rectum; 2001 Mar; 44(3):364-72; discussion 372-3. PubMed ID: 11289282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between KRAS and NRAS mutational status and clinicopathological features in 414 cases of metastatic colorectal cancer in Morocco: the largest North African case series.
    Mahdi Y; Khmou M; Souadka A; Agouri HE; Ech-Charif S; Mounjid C; Khannoussi BE
    BMC Gastroenterol; 2023 Jun; 23(1):193. PubMed ID: 37277698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas.
    Jesinghaus M; Konukiewitz B; Keller G; Kloor M; Steiger K; Reiche M; Penzel R; Endris V; Arsenic R; Hermann G; Stenzinger A; Weichert W; Pfarr N; Klöppel G
    Mod Pathol; 2017 Apr; 30(4):610-619. PubMed ID: 28059096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
    Hwang DH; Sholl LM; Rojas-Rudilla V; Hall DL; Shivdasani P; Garcia EP; MacConaill LE; Vivero M; Hornick JL; Kuo FC; Lindeman NI; Dong F
    J Thorac Oncol; 2016 Apr; 11(4):496-503. PubMed ID: 26829311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma.
    Rall CJ; Yan YX; Graeme-Cook F; Beauchamp R; Yandell DW; Povoski SP; Rustgi AK
    Pancreas; 1996 Jan; 12(1):10-7. PubMed ID: 8927612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas.
    Crumley SM; Pepper KL; Phan AT; Olsen RJ; Schwartz MR; Portier BP
    Arch Pathol Lab Med; 2016 Jun; 140(6):529-35. PubMed ID: 26536055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic and carcinogenetic appraisal of DNA replication error in sporadic T3N0M0 stage colorectal cancer after curative resection.
    Liang JT; Chang KJ; Chen JC; Lee CC; Cheng YM; Hsu HC; Chien CT; Wang SM
    Hepatogastroenterology; 1999; 46(26):883-90. PubMed ID: 10370632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
    Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer.
    Sanchez JA; Dejulius KL; Bronner M; Church JM; Kalady MF
    Inflamm Bowel Dis; 2011 Sep; 17(9):1966-70. PubMed ID: 21618350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of KRAS Mutations in Gastrointestinal Tract Adenocarcinomas Reveals Site-Specific Mutational Signatures.
    Wang L; Saeedi BJ; Mahdi Z; Krasinskas A; Robinson B
    Mod Pathol; 2023 Feb; 36(2):100014. PubMed ID: 36853786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiclonal colorectal cancers with divergent histomorphological features and RAS mutations: one cancer or separate cancers?
    Lin MT; Zheng G; Tseng LH; Zhang P; Ling H; Azad N; Gocke CD; Montgomery E; Eshleman JR
    Hum Pathol; 2020 Apr; 98():120-128. PubMed ID: 32171651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of Ki-ras mutations and DNA alkylation in colorectal tissue from individuals living in Manchester.
    Jackson PE; Hall CN; Badawi AF; O'Connor PJ; Cooper DP; Povey AC
    Mol Carcinog; 1996 May; 16(1):12-9. PubMed ID: 8634090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and mutation analyses of P53R2, a newly identified p53 target for DNA repair in human gastric carcinoma.
    Byun DS; Chae KS; Ryu BK; Lee MG; Chi SG
    Int J Cancer; 2002 Apr; 98(5):718-23. PubMed ID: 11920641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians.
    Malhotra P; Anwar M; Nanda N; Kochhar R; Wig JD; Vaiphei K; Mahmood S
    Tumour Biol; 2013 Jun; 34(3):1901-11. PubMed ID: 23526092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational analysis and clinical correlation of metastatic colorectal cancer.
    Russo AL; Borger DR; Szymonifka J; Ryan DP; Wo JY; Blaszkowsky LS; Kwak EL; Allen JN; Wadlow RC; Zhu AX; Murphy JE; Faris JE; Dias-Santagata D; Haigis KM; Ellisen LW; Iafrate AJ; Hong TS
    Cancer; 2014 May; 120(10):1482-90. PubMed ID: 24500602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synchronous colon carcinomas: molecular-genetic evidence for multicentricity.
    Koness RJ; King TC; Schechter S; McLean SF; Lodowsky C; Wanebo HJ
    Ann Surg Oncol; 1996 Mar; 3(2):136-43. PubMed ID: 8646513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.
    Di Bartolomeo M; Pietrantonio F; Perrone F; Dotti KF; Lampis A; Bertan C; Beretta E; Rimassa L; Carbone C; Biondani P; Passalacqua R; Pilotti S; Bajetta E;
    Target Oncol; 2014 Jun; 9(2):155-62. PubMed ID: 23821376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.